InsidersTradesSigma
Track the Senseonics Holdings, Inc. share price and the full management transaction log of the company, a listed issuer based in United States. Shares are quoted on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Senseonics Holdings, Inc. has recorded 134 reports. Market capitalisation: €481.7m. The latest transaction was reported on 20 August 2026 (Acquisition). Among the most active insiders: Fiorentino Edward. All data is accessible without an account.
134
Insider Decl.
n/a
Thresholds
€720,538
8 ops.
Buy Volume
€113,731
2 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Senseonics Holdings, Inc. Buy (bullish), based on 5 analysts. Average price target: US$13.40.
46Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 25,828 of 29,063 companies
23.1
score / 100
Value14
Quality32
FCF yld-12%
Earn yld-14%
EV/EBITDA·
ROE-118%
Gross mgn45%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 20 August 2026
Declarations134 total
13,953.284 shares@ US$8.98Common StockSEC:0001270735-26-000014:0
Canonical exit: 17 Nov 2026 (T+90)
9,852 shares0Common StockSEC:0001666964-26-000002:0
9,852 shares0Common StockSEC:0001666972-26-000006:0
553,701 shares0Common StockSEC:0001667588-26-000006:0
90,253 shares0Common StockSEC:0001542377-26-000002:0
2,124 shares@ US$6.653.5% of flowCommon StockSEC:0001666972-26-000004:0
1,221 shares@ US$6.658.3% of flowCommon StockSEC:0001666995-26-000004:0
2,218 shares@ US$6.652.6% of flowCommon StockSEC:0001270735-26-000006:0
1,936 shares@ US$6.658.9% of flowCommon StockSEC:0001683354-26-000004:0
17,225 shares@ US$5.796.2% of flowCommon StockSEC:0001667588-26-000002:0
Canonical exit: 11 Jun 2026 (T+90)
17,500 shares@ US$5.7314.7% of flowCommon StockSEC:0001270735-26-000004:0
Canonical exit: 11 Jun 2026 (T+90)
19,673 shares@ US$0.4137.0% of flowCommon StockSEC:0001666995-25-000004:0
31,174 shares@ US$0.4137.5% of flowCommon StockSEC:0001683354-25-000004:0
34,200 shares@ US$0.4137.2% of flowCommon StockSEC:0001666972-25-000004:0
35,714 shares@ US$0.4132.1% of flowCommon StockSEC:0001270735-25-000004:0
17,069 shares@ US$0.4767.5% of flowCommon StockSEC:0001415889-25-019315:0
30,987 shares@ US$0.4762.5% of flowCommon StockSEC:0001415889-25-019314:0
29,674 shares@ US$0.4767.7% of flowCommon StockSEC:0001415889-25-019313:0
27,048 shares@ US$0.4768.0% of flowCommon StockSEC:0001415889-25-019312:0
27,263 shares@ US$0.513.1% of flowCommon StockSEC:0001415889-25-017602:0
28,853 shares@ US$0.515.5% of flowCommon StockSEC:0001415889-25-017601:0
58,761 shares@ US$0.513.8% of flowCommon StockSEC:0001415889-25-017600:0
79,646 shares@ US$0.512.7% of flowCommon StockSEC:0001415889-25-017598:0
35,784 shares@ US$0.514.2% of flowCommon StockSEC:0001415889-25-017599:0
167,085 shares@ US$0.5513.6% of flowCommon StockSEC:0001415889-25-013692:0
25 of 134 declarations
关于 Senseonics Holdings, Inc.
Senseonics Holdings, Inc. 是一家在美国上市的医疗技术公司，在纳斯达克交易，股票代码为 SENS。该公司总部位于美国马里兰州日耳曼敦，专注于为糖尿病患者开发、制造和商业化长期植入式连续血糖监测 (CGM) 系统。其核心业务是 Eversense 系列，这是一个差异化的 CGM 平台，围绕植入皮下的植入式传感器构建，并与可穿戴发射器和移动应用程序配对。这种设计使 Senseonics 有别于传统的外部 CGM 系统，是其投资案例的核心。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1616543/000110465926022298/sens-20251231x10k.htm?utm_source=openai)） 从公司历史的角度来看，Senseonics 一直围绕专有的植入式传感器技术构建，旨在提高血糖监测的便利性并减少传感器更换的频率。该公司是一家特拉华州公司，长期以来一直在马里兰州基地运营。随着时间的推移，它通过连续的 Eversense 迭代扩展了其商业足迹，包括于2022年2月获得 FDA 批准的 Eversense E3，以及于2024年9月在美国获准销售的 Eversense 365。这些里程碑很重要，因为它们表明该公司从单一产品创新者向更广泛的商业糖尿病技术平台的转变。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1616543/000155837025006983/sens-20250331x10q.htm?utm_source=openai)） 在运营方面，Senseonics 仍然是一家高度专注的单一平台公司，专注于糖尿病护理。其业务包括植入式 CGM 系统的开发、制造和商业化，以及监管文件中提及的 Gemini 和 Freedom 等下一代项目。该公司采用混合商业模式，将直接商业化与第三方分销合作伙伴关系相结合，在这些合作伙伴已经拥有销售基础设施和医疗保健关系的市场上。这种结构使 Senseonics 能够在追求美国市场的同时，也在选定的海外市场保持业务。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1616543/000110465926022298/sens-20251231x10k.htm?utm_source=openai)） 在竞争方面，Senseonics 在更广泛的 CGM 市场中占据着一个专业利基。其主要区别在于其植入式传感器的长寿命以及与更少传感器更换相关的便利性主张。另一方面，采用率在很大程度上取决于保险覆盖范围、医生意识和获得受过培训的植入者。换句话说，技术是差异化的，但商业化仍然对执行敏感。（[sec.gov](https://www.sec.gov/Archives/edgar/data/0001616543/000110465926022298/sens-20251231x10k.htm?utm_source=openai)） 最近的发展对投资者尤为重要。2026年，Senseonics 完成了 Eversense 在美国商业责任从 Ascensia 回归公司的过渡，这意味着公司现在直接获取美国产品收入。管理层还继续强调 Eversense 365 的推出、支付方覆盖范围的扩大以及在欧洲和欧洲、中东和非洲地区的进一步商业化。这些是重要的近期催化剂，因为它们影响收入构成、经营杠杆和增长的可持续性。（[sec.gov](https://www.sec.gov/Archives/edgar/data/0001616543/000110465926022298/sens-20251231x10k.htm?utm_source=openai)）
